Welcome to our dedicated page for Azitra SEC filings (Ticker: AZTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Azitra Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on precision dermatology. Recent disclosures cover proxy materials for annual and special stockholder meetings, shareholder voting procedures, board and governance matters, and meeting-status updates filed on Form 8-K.
Azitra's SEC reports also describe material agreements and capital-structure changes, including private placement securities, Series A preferred stock and Series B and Series C warrants. Other filings address furnished financial results, pipeline business updates, use of financing proceeds for research and development and working capital, and NYSE American continued-listing compliance matters tied to stockholders' equity standards.
Azitra, Inc. adjourned its 2026 annual meeting of stockholders after failing to reach a quorum. A quorum would have required shares representing 33 1/3% of the common stock entitled to vote, but only about 17% of eligible shares were represented by proxy.
The meeting, originally convened on June 4, 2026, will reconvene virtually on June 15, 2026, at 11:00 a.m. Eastern Time via www.proxydocs.com/AZTR. Stockholders of record as of April 24, 2026 remain entitled to vote, and previously submitted proxies remain valid unless changed.
Azitra’s press release explains that stockholders can vote or change prior votes by mail, internet, telephone, or during the reconvened virtual meeting, following instructions in the definitive proxy statement filed on May 8, 2026.
Azitra, Inc. is postponing the business of its 2026 annual stockholders’ meeting due to a minor administrative delay in mailing proxy materials. The company will open the meeting on June 4, 2026 at 11:00 a.m. Eastern Time and immediately adjourn it without conducting other business.
The annual meeting will reconvene virtually on June 15, 2026 at 11:00 a.m. Eastern Time at www.proxydocs.com/AZTR. The record date remains April 24, 2026, and the proposals to be voted on are unchanged. Stockholders who already voted and do not wish to change their vote do not need to take further action.
Azitra, Inc. is registering 255,699,381 shares of common stock for resale by existing investors. These shares come from the conversion of 10,485 shares of Series A preferred stock into 85,223,129 conversion shares and the potential exercise of Series B and C warrants for 170,466,252 warrant shares, including related pre-funded warrants. Azitra is not selling shares in this offering and will not receive proceeds from stockholder resales, though full cash exercise of the warrants could bring in approximately $21 million. Common stock outstanding was 16,192,438 shares as of May 19, 2026, and would increase to 271,865,819 shares if all preferred, warrants and pre-funded warrants are fully exercised. The company reports a going concern warning, limited cash resources, significant potential dilution, and an existing NYSE American listing compliance plan.
Azitra, Inc. reported Q1 2026 results showing higher operating investment and a stronger cash position while advancing its dermatology pipeline. Research and development expenses were $1.6 million versus $1.3 million a year earlier, and general and administrative expenses were $2.4 million versus $1.9 million. Net loss was $3.9 million compared with $3.1 million in Q1 2025, reflecting increased spending to support programs.
As of March 31, 2026, Azitra held $10.1 million in cash and cash equivalents, up from $2.1 million at year-end 2025, and total assets were $12.1 million. The company highlighted clinical progress for ATR-12 in Netherton syndrome, ATR-04 for EGFR inhibitor–associated rash, ATR-01 in ichthyosis vulgaris, and a new ATR-COSF cosmeceutical initiative targeting cosmetic applications, supported by a previously priced private placement of up to approximately $10.5 million with additional potential warrant proceeds.
Azitra, Inc. reported a net loss of $3.9 million for the quarter ended March 31, 2026, compared with $3.1 million a year earlier, as it continues pre‑revenue development of precision dermatology therapies.
Cash and cash equivalents rose to $10.1 million from $2.1 million at December 31, 2025, mainly from a $10.4 million Series A preferred financing and draws on an equity line of credit. Stockholders’ equity increased to $10.5 million, but the company has an accumulated deficit of about $72.4 million and used $2.5 million of cash in operating activities this quarter.
Management states there is substantial doubt about the company’s ability to continue as a going concern over the next twelve months without additional financing. Azitra also remains subject to NYSE American continued listing requirements after previously receiving a deficiency notice, and is relying on equity offerings, an equity line of credit with up to $20 million capacity, and newly issued Series A preferred stock and large warrant packages that could convert into or be exercisable for hundreds of millions of common shares.
Azitra, Inc. is asking stockholders at its virtual June 4, 2026 annual meeting to approve several major capital structure changes and routine governance items. Stockholders will elect four directors, including CEO Francisco D. Salva and COO Travis Whitfill, and vote on ratifying Grassi & Co., CPAs, P.C. as auditor for 2026.
The company seeks to amend its charter to increase authorized common stock from 200,000,000 to 750,000,000 shares, citing forecasted capital-raising needs to fund product development and other uses. As of April 24, 2026, 16,192,438 shares of common stock were outstanding, with a very large number of additional shares reserved, primarily for warrants.
Azitra also requests authority for the Board to implement one or more reverse stock splits at a ratio between 1-for-2 and 1-for-30 to help support compliance with NYSE American listing requirements. Additional proposals seek NYSE American–required approval for potential issuances of more than 19.99% of outstanding shares under a 2025 Alumni Capital LP agreement and a March 18, 2026 financing involving Series A Preferred Stock and Series B and C Warrants, plus an amendment and restatement of the 2023 Stock Incentive Plan to increase its share reserve and permission to adjourn the meeting if more votes are needed.
Azitra, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 4, 2026. The proxy seeks approval for nine proposals, including an amendment to increase authorized common shares from 200,000,000 to 750,000,000, shareholder authorization enabling the Board to effect one or more reverse stock splits at ratios between 1-for-2 and 1-for-30, approval related to issuances exceeding 19.99% under two recent securities purchase agreements, an amendment to increase the 2023 Stock Incentive Plan reserve, election of four directors, and ratification of the independent auditor. Shares outstanding were 16,192,438 as of April 24, 2026.
Azitra, Inc. Chief Financial Officer Norm Staskey received a grant of 35,524 stock options to buy common shares. The options have an exercise price of $0.2127 per share and expire on April 20, 2036. After this grant, Staskey holds 35,524 options directly.
One third of the options will vest on the one-year anniversary of the grant date, and the remaining two thirds will vest in equal monthly installments over the following two years. This is a compensation-related award rather than an open-market purchase or sale.